Figure 4.

Effect of different pharmacological treatments on brain bioluminescence modulation. MITO-Luc mice received, in conjunction with bilirubin injection, one of the following treatments: daily intra peritoneal (i.p.) administration of human serum albumin (Alb) (2.5 g/kg body weight) for 2 days before bilirubin (Bili) administration (Alb + Bili group); administration of minocycline (Mnc) (50 mg/kg) i.p. 30 min before and 2 h after bilirubin injection (Mnc + Bili group); i.p. administration of sulphadimethoxine (Sulpha) (200 mg/kg body weight) 2 h before bilirubin administration (Sulpha + Bili group). Quantification of BLI signals in the regions of interest in the brain area were quantified 5 h after bilirubin administration and compared to the signal assessed in the same animals 3 days before the administration of the different substances (referred as “Pre inj” for “pre injection”), and with a group of animals receiving saline solution only (Saline). n = 25 at the pre injection assessment; then the animals were randomly divided in groups of 5 mice each. The significance of differences of the bilirubin group (Bili) vs. the controls and experimental groups are shown. In particular, (*) indicates p ≤ 0.05; (#) p > 0.05 between bilirubin and albumin + bilirubin groups.